Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)

Introduction PF-06438179, a potential biosimilar to Remicade® (infliximab, Janssen Biotech, Inc.), is a chimeric mouse–human monoclonal antibody targeting human tumor necrosis factor alpha (TNF).